Meningitis in infancy in England and Wales: follow up at age 5 years.
about
Fluid therapy for acute bacterial meningitisFluid therapy for acute bacterial meningitisFluid therapy for acute bacterial meningitisInvasive Enterobacter sakazakii disease in infantsMeningococcal B Vaccination (4CMenB) in Infants and ToddlersBacterial meningitis in infantsShould Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis.Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis.Neonatal meningitis.Oxidative stress and S-100B protein in children with bacterial meningitis.Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants.Breast milk and Group B streptococcal infection: vector of transmission or vehicle for protection?Disease burden and antimicrobial resistance of invasive group B streptococcus among infants in China: a protocol for a national prospective observational studyComparison of molecular serotyping approaches of Streptococcus agalactiae from genomic sequences.Association of kynurenine aminotransferase II gene C401T polymorphism with immune response in patients with meningitis.IL-10 administration reduces PGE-2 levels and promotes CR3-mediated clearance of Escherichia coli K1 by phagocytes in meningitisPrognostic factors related to sequelae in childhood bacterial meningitis: data from a Greek meningitis registry.Systematic review: neonatal meningitis in the developing world.Etiology and antimicrobial resistance patterns of acute bacterial meningitis in children: a 10-year referral hospital-based study in northwest iranCognitive deficits following exposure to pneumococcal meningitis: an event-related potential studyPrevention of group B streptococcal neonatal disease revisited. The DEVANI European project.Restoration of Akt activity by the bisperoxovanadium compound bpV(pic) attenuates hippocampal apoptosis in experimental neonatal pneumococcal meningitis.Multilocus sequence types, serotypes, and variants of the surface antigen PspA in Streptococcus pneumoniae isolates from meningitis patients in Poland.Fluid therapy for acute bacterial meningitis.New therapies and vaccines for bacterial meningitis.Using an evidence-based approach to a paediatric problem.Group B Streptococcus engages an inhibitory Siglec through sialic acid mimicry to blunt innate immune and inflammatory responses in vivoAntibody-mediated complement C3b/iC3b binding to group B Streptococcus in paired mother and baby serum samples in a refugee population on the Thailand-Myanmar border.Long term follow up after meningitis in infancy: behaviour of teenagers.Long term outcome of neonatal meningitisBurden of invasive group B Streptococcus disease and early neurological sequelae in South African infants.A putative role for homocysteine in the pathophysiology of acute bacterial meningitis in childrenWhole-Genome Comparison Uncovers Genomic Mutations between Group B Streptococci Sampled from Infected Newborns and Their Mothers.Vaccination against group B streptococcus.What the teacher needs to know.Effect of meningitis in infancy on school-leaving examination results.Human milk oligosaccharides inhibit growth of group B Streptococcus.Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870Association between cerebrospinal fluid S100B protein and neuronal damage in patients with central nervous system infections.The Burden of Infant Meningococcal Disease in the United States.
P2860
Q24194762-FA13DFBE-52CA-48CA-B353-6CF9EB977847Q24242830-A490F895-8CEC-4709-A2B5-96DB34BEF961Q24246386-B4AEEB2A-54A8-4A2D-ACDB-FEE2D2C31236Q24628779-99C83C2A-374F-4FF4-8035-81BEBCB8FB40Q26782285-D98C1D9F-C8DD-4275-B0DE-8FD89CD31E41Q28082173-3899C8C3-F882-4E7F-9415-BD1C5AF7BEB7Q30457467-9A8E66BE-6472-4B3B-BA18-120C9C1B4780Q30540523-98406351-F7AF-4BF8-9B79-58395B787C02Q30921313-0BF43E8A-5D9B-458F-8B80-C93BABF5A00AQ33509386-7E0A2172-DC4A-491A-B069-AC67E934DA10Q33525194-EC39C2AA-5432-4209-8087-BC70DBE548C3Q33682806-20D5FCA1-C0B2-435C-931D-57B4B496E7A1Q33750103-119C8272-529F-4E9F-9356-88EE4638E5BEQ33755860-343B8A13-0FA3-4B26-A44C-EED918CB054EQ33865211-543EDFF1-6290-47B3-A96B-D1200AEB788BQ33902365-D135323B-0CAD-48C3-AD8C-853504E85CBCQ33986703-B450767C-5C25-4110-8F47-343FEC7FD2BEQ34170056-5E3B561E-94E6-451C-ACE8-E08DBE04D64AQ34197373-3A779ABF-0040-4B68-BD5F-E2D2BEB6238BQ34214093-F55A9734-6F4B-4243-BADD-58E1592A8A15Q34252808-240B402E-AAF4-4EBA-AD86-D4498CC5C509Q34316072-C5C5C967-ACF8-46C4-90BE-5B429109907DQ34325877-7944000B-89D8-4F3C-96A0-EBF1A1672678Q34544083-2F1C7CBD-5B60-407E-9F6B-DB5086602110Q34768547-A9086EFA-44FE-4845-950E-92AE8EB3635AQ35072328-9E2929E8-4BA9-4F4F-8AEF-58F5DF59F474Q35082207-ADEBE81B-9D71-4C67-8D82-08FE095355DDQ35122775-39C6355C-B220-4BC3-A35D-E0B54A511D7BQ35276203-AEACACBD-706E-4D3E-9BA3-65B47BA45E3DQ35293335-AF4EA07F-DFC8-4E24-8005-A2C4B74774C0Q35306303-09930C55-B7A5-4A33-9649-015DDDB616D0Q35493302-01197A96-AF9F-45A7-84EA-4F72F40A0DACQ36070056-64E15ACD-FB5D-4D8B-A738-B051AA4FD104Q36124960-30A46BEB-9EF2-4AD8-942E-0E208AD5FDD8Q36154987-EC015552-4046-4F8D-9E33-23D0FAFFA04FQ36155056-C2ACAC17-7B21-49B5-BCD0-04234FCF663CQ36349117-146617DF-A30A-405F-81F8-F26418DA118BQ36370598-9939D79E-9E1E-4F8C-AC7B-5C26CA700CD3Q36793165-FBC0FF1C-A3F5-470B-B4F3-D79DEC9A1B17Q36851143-A2CB66F7-689F-4EA1-8AF3-219B714ABB04
P2860
Meningitis in infancy in England and Wales: follow up at age 5 years.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Meningitis in infancy in England and Wales: follow up at age 5 years.
@en
type
label
Meningitis in infancy in England and Wales: follow up at age 5 years.
@en
prefLabel
Meningitis in infancy in England and Wales: follow up at age 5 years.
@en
P2093
P2860
P356
P1433
P1476
Meningitis in infancy in England and Wales: follow up at age 5 years.
@en
P2093
P2860
P304
P356
10.1136/BMJ.323.7312.533
P407
P577
2001-09-01T00:00:00Z